HONG KONG: Capital Group Cos, the US asset manager that has been backing startups in emerging markets, is in talks to invest in Chinese biopharmaceutical firm Innovent Biologics Inc, people with knowledge of the matter said.
Capital Group would join other investors in a funding round for Innovent ahead of a planned listing, according to the people.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
